This activity is expired and is no longer available for CME credit.


Emerging Data in the Management of Ulcerative Colitis: Updates from Washington, DC 2015

Author(s)/Faculty: William J. Sandborn, MD
Release Date: 7/29/2015Expiration Date: 7/28/2016
Credit Type: CMENumber of Credits: 0
Content Type: MultimediaProvider:
Ulcerative colitis (UC) is the most common inflammatory bowel disease (IBD) worldwide, with approximately 600,000 Americans living with UC. Ulcerative colitis is characterized by an overactive immune response to the gut enteric flora, resulting in bowel inflammation and ulceration. As one study demonstrated that approximately 80% of studied patients with IBD received suboptimal therapy, there is substantial room for improvement in the care of patients with IBD. Several agents with a variety of mechanisms of action are now in clinical development or available for the treatment of UC. As the therapeutic landscape for UC continues to evolve, physicians need to be aware of how these agents can be used to optimize outcomes for patients. This CME activity addresses the mechanisms of action, efficacy and safety of emerging therapies for the management of moderate-to-severe ulcerative colitis.